Bone health in cancer: ESMO Clinical Practice Guidelines

被引：328

作者：

Coleman, R. ^{[1
]}

Hadji, P. ^{[2
,3
]}

Body, J-J ^{[4
]}

Santini, D. ^{[5
]}

Chow, E. ^{[6
]}

Terpos, E. ^{[7
]}

Oudard, S. ^{[8
]}

Bruland, O. ^{[9
,10
]}

Flamen, P. ^{[11
]}

Kurth, A. ^{[12
,13
]}

Van Poznak, C. ^{[14
]}

Aapro, M. ^{[15
]}

Jordan, K. ^{[16
]}

机构：

[1] Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England

[2] Frankfurt Ctr Bone Hlth, Frankfurt, Germany

[3] Philipps Univ Marburg, Marburg, Germany

[4] Univ Libre Bruxelles, CHU Brugmann, Brussels, Belgium

[5] Univ Campus Biomed, Med Oncol Dept, Rome, Italy

[6] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada

[7] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

[8] Paris Descartes Univ, Georges Pompidou Hosp, Dept Med Oncol, Paris, France

[9] Univ Oslo, Inst Clin Med, Oslo, Norway

[10] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Oncol, Oslo, Norway

[11] Univ Libre Bruxelles, Inst Jules Bordet, Dept Nucl Med, Brussels, Belgium

[12] Community Clin Middle Rhine, Dept Orthopaed & Trauma Surg, Campus Kemperhof, Koblenz, Germany

[13] Univ Med Mainz, Major Teaching Hosp, Mainz, Germany

[14] Univ Michigan, Ann Arbor, MI 48109 USA

[15] Genolier Canc Ctr, Genolier, Switzerland

[16] Heidelberg Univ, Dept Med Hematol Oncol & Rheumatol 5, Heidelberg, Germany

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷 / 12期

关键词：

bone metastases; cancer treatment-induced bone loss; bone-targeted agents; Clinical Practice Guidelines; diagnosis; treatment; follow-up; EARLY BREAST-CANCER; ZOLEDRONIC ACID; MULTIPLE-MYELOMA; DOUBLE-BLIND; SOLID TUMORS; OPEN-LABEL; DENOSUMAB; METASTASES; PHASE-3; SURVIVAL;

D O I：

10.1016/j.annonc.2020.07.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：1650 / 1663

页数：14

共 44 条

[1] Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial [J].

Barrett-Lee, Peter ;

Casbard, Angela ;

Abraham, Jacinta ;

Hood, Kerenza ;

Coleman, Robert ;

Simmonds, Peter ;

Timmins, Hayley ;

Wheatley, Duncan ;

Grieve, Robert ;

Griffithst, Gareth ;

Murray, Nick .

LANCET ONCOLOGY, 2014, 15 (01) :114-122

[2] Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management [J].

Black, Dennis M. ;

Abrahamsen, Bo ;

Bouxsein, Mary L. ;

Einhorn, Thomas ;

Napoli, Nicola .

ENDOCRINE REVIEWS, 2019, 40 (02) :333-368

[3] Bone health in the elderly cancer patient: A SIOG position paper [J].

Body, J. J. ;

Terpos, E. ;

Tombal, B. ;

Hadji, P. ;

Arif, A. ;

Young, A. ;

Aapro, M. ;

Coleman, R. .

CANCER TREATMENT REVIEWS, 2016, 51 :46-53

[4] Skeletal Metastasis Evaluation Value and Impact of PET/Computed Tomography on Diagnosis, Management and Prognosis [J].

Broski, Stephen M. ;

Young, Jason R. ;

Kendi, Ayse T. ;

Subramaniam, Rathan M. .

PET CLINICS, 2019, 14 (01) :103-+

[5] Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials [J].

Coleman, R. ;

Powles, T. ;

Paterson, A. ;

Gnant, M. ;

Anderson, S. ;

Diel, I. ;

Gralow, J. ;

von Minckwitz, G. ;

Moebus, V. ;

Bergh, J. ;

Pritchard, K. I. ;

Bliss, J. ;

Cameron, D. ;

Evans, V. ;

Pan, H. ;

Peto, R. ;

Bradley, R. ;

Gray, R. ;

Bartsch, R. ;

Dubsky, P. ;

Fesl, C. ;

Fohler, H. ;

Greil, R. ;

Jakesz, R. ;

Lang, A. ;

Luschin-Ebengreuth, G. ;

Marth, C. ;

Mlineritsch, B. ;

Samonigg, H. ;

Singer, C. F. ;

Steger, G. G. ;

Stoeger, H. ;

Olivotto, I. ;

Ragaz, J. ;

Christiansen, P. ;

Ejlertsen, B. ;

Ewertz, M. ;

Jensen, M-B ;

Moller, S. ;

Mouridsen, H. T. ;

Eiermann, W. ;

Hilfrich, J. ;

Jonat, W. ;

Kaufmann, M. ;

Kreienberg, R. ;

Schumacher, M. ;

Blohmer, J. U. ;

Costa, S. D. ;

Eidtmann, H. ;

Gerber, B. .

LANCET, 2015, 386 (10001) :1353-1361

[6] Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial [J].

Coleman, Robert ;

Finkelstein, Dianne M. ;

Barrios, Carlos ;

Martin, Miguel ;

Iwata, Hiroji ;

Hegg, Roberto ;

Glaspy, John ;

Montano Perianez, Alvaro ;

Tonkin, Katia ;

Deleu, Ines ;

Sohn, Joohyuk ;

Crown, John ;

Delaloge, Suzette ;

Dai, Tian ;

Zhou, Ying ;

Jandial, Danielle ;

Chan, Arlene .

LANCET ONCOLOGY, 2020, 21 (01) :60-72

[7]

Coleman R, 2019, BREAST, V48, pS92, DOI 10.1016/S0960-9776(19)31133-6

[8] Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial [J].

Coleman, Robert ;

Hall, Andrew ;

Albanell, Joan ;

Hanby, Andrew ;

Bell, Richard ;

Cameron, David ;

Dodwell, David ;

Marshall, Helen ;

Jean-Mairet, Joel ;

Tercero, Juan-Carlos ;

Rojo, Federico ;

Gregory, Walter ;

Gomis, Roger R. .

LANCET ONCOLOGY, 2017, 18 (11) :1543-1552

[9] Consensus on the utility of bone markers in the malignant bone disease setting [J].

Coleman, Robert ;

Costa, Luis ;

Saad, Fred ;

Cook, Richard ;

Hadji, Peyman ;

Terpos, Evangelos ;

Garnero, Patrick ;

Brown, Janet ;

Body, Jean-Jacques ;

Smith, Matthew ;

Lee, Ker-Ai ;

Major, Pierre ;

Dimopoulos, Meletios ;

Lipton, Allan .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 80 (03) :411-432

[10] Clinical features of metastatic bone disease and risk of skeletal morbidity [J].

Coleman, Robert E. .

CLINICAL CANCER RESEARCH, 2006, 12 (20) :6243S-6249S

← 1 2 3 4 5 →